Strategies of treatment with olanzapine in schizophrenic patients during stable phase: Results of a pilot study

European Neuropsychopharmacology

Volumn 18, Issue 9, 2008, Pages 646-652

  Rouillon, Frédéric ^a   Chartier, Florence ^b   Gasquet, Isabelle ^c  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b Lilly France   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Dose; Olanzapine; Schizophrenia; Stable phase

Indexed keywords

OLANZAPINE;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FRANCE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; EMERGENCY SERVICES, PSYCHIATRIC; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 48849085071     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.04.012     Document Type: Article

References (23)

1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am. J. Psychiatry 154 4 (1997) 1-63 (supplement)
2. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161 2 (2004) 1-56 (Suppl)
3. Auquier P., Simeoni M.C., Sapin C., Reine G., Aghababian V., Cramer J., and Lancon C. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophr. Res. 63 1-2 (2003) 137-149 Sept 1
4. Beasley Jr. C.M., Sutton V.K., Hamilton S.H., Walker D.J., Dossenbach M., Taylor C.C., Alaka K.J., Bykowski D., and Toleffsson G.D. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J. Clin. Psychopharmacol. 23 6 (2003) 582-594
5. Concato J., Shah N., and Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342 (2000) 1887-1892
6. Csernansky J.G., Mahmoud R., and Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. Vol. 346 (2002) n°1
7. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J. Clin. Psychiatry 64 Suppl 12 (2003) 1-100
8. Lader M. What is relapse in schizophrenia?. Int. Clin. Psychopharmacol. 9 suppl 5 (1995) 5-9 Jan
9. Leblanc G., Cormier H., Gagne M.A., Vaillancourt S., et al. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses. Can. J. Psychiatry 395 4 (1994) 223-229
10. Leucht S., Pitschel-walz G., Abraham D., et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35 (1999) 51-68
11. Marder S.R. Antipsychotic drugs and relapse prevention. Schizophr. Res. 35 (1999) S87-S92
12. Olie, J., Vanelle, J., Duaux, E. (1994). Faut-il instaurer des cures continues ou discontinues? Comment et quand arrêter le traitement neuroleptique ? Problèmes posés par l'observance du traitement. In: ANDEM, eds. Stratégies thérapeutiques à long terme dans les psychoses schizophréniques. Conférence de consensus: texte des experts. ed. Paris: Frison-Roche; 95108.
13. Palmer B.A., Pankratz V.S., and Bostwick J.M. The lifetime risk of suicide in schizophrenia: a reexamination. Arch. Gen. Psychiatry 62 (2005) 247-253 Mar
14. Sacristan J.A., Gomez J.C., Montejo A.L., Vieta E., Gregor K.J., and EFESO Study Group. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. Clin. Ther. 22 (2000) 583-599
15. Schooler N.R. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr. Bull. 17 (1991) 311-324
16. Schooler N.R. Reducing dosage in maintenance treatment of schizophrenia. Review and prognosis. Br. J. Psychiatry (1993) 58-65 Suppl
17. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M., Bellack A.S., Glick I.D., Hargreaves W.A., Kane J.M., Ninan P.T., Frances A., Jacobs M., Lieberman J.A., Mance R., Simpson G.M., and Woerner M.G. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch. Gen. Psychiatry 54 5 (1997) 453-463
18. Shriqui C.J. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Can. J. Psychiatry 40 (1995) S38-S48 (7 Suppl. 2)
19. Tandon R., Belmaker R.H., Gattaz W.F., Lopez-Ibor Jr. J.J., Okasha A., Singh B., Stein D.J., Olie J.P., Fleischhacker W.W., Moeller H.J., and for the Section of Pharmacopsychiatry, and World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 100 (2008) 20-38
20. Tort A.B.L., Souza D.O., and Lara D.R. Half the dose of antipsychotic in case of extrapyramidal symptoms. Schizophr. Res. 10/15 78 (2-3) (2005) 347-349
21. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C.M., and Toleffson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 5 (1997) 407-418 Oct
22. Tran P.V., Dellva M.A., Toleffson G.D., Wentley A.L., and Beasley Jr. C.M. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br. J. Psychiatry 172 (1998) 499-505 Jun
23. Woods S.W. Review: high doses of antipsychotic drugs are no more or less effective than medium doses in people with schizophrenia. Evid. Based Ment. Health 7 4 (2004) 106 November 1, 2004